NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

My guess, $50/sh by 1/1/2023, assuming approval and a partnership.

Because approval means
- DCVax-L gains steady adoption on a country by country basis globally during the next 12 months as the best-in-class, first line, standard of care treatment for GBM
- DCVax is validated as the safe, efficacious, autologous immunotherapy platform.
- DCVax-Direct narrative as a possible disrupter to current solid tumor cancer drug companies gets legs, so the market cap then begins to reflect this valuation because it is currently not.

Because Partnership means
- A strategic decision was made that Big Pharma will end up paying manyfold more in a buyout a couple years later, than now. Because by then, all will know and shall bow to the dendritic cell and immune system.
- It is not a “go-it-alone” but rather a gain-commercial-partner strategy.
- Maybe a partnership strategy for DCVax-Direct, in the same way Merck licenses Keytruda for combination treatment clinical trial studies, as in 200 clinical trials across 30 tumor types.